Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ritlecitinib study in nonsegmental vitiligo
2022-501668-16-00Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in nonsegmental vitiligo comparing Ritlecitinib with Placebo (2 arms). Primary endpoints: F-VASI75 response at Week 52, Treatment-emergent adverse events and 1 more. Started Jun 2023; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on 2022-501668-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501668-16-00.